| Identification | Back Directory | [Name]
Urea, N-[2-[6,7-dihydro-9,10-dimethoxy-4-oxo-2-[(2,4,6-trimethylphenyl)imino]-2H-pyrimido[6,1-a]isoquinolin-3(4H)-yl]ethyl]- | [CAS]
298680-25-8 | [Synonyms]
LS-193855
RPL-554-d4
Urea, N-[2-[6,7-dihydro-9,10-dimethoxy-4-oxo-2-[(2,4,6-trimethylphenyl)imino]-2H-pyrimido[6,1-a]isoquinolin-3(4H)-yl]ethyl]- | [Molecular Formula]
C26H31N5O4 | [MDL Number]
MFCD09970918 | [MOL File]
298680-25-8.mol | [Molecular Weight]
477.56 |
| Chemical Properties | Back Directory | [density ]
1.29±0.1 g/cm3(Predicted) | [storage temp. ]
-10 to -25°C | [solubility ]
DMSO: 2mg/mL, clear (Warmed) | [form ]
powder | [pka]
13.73±0.46(Predicted) | [color ]
white to beige |
| Hazard Information | Back Directory | [Uses]
RPL 554 is a known drug candidate for respiratory diseases, particularly in patients with asthma or chronic obstructive pulmonary diseases. | [Biological Activity]
RPL554 (Ensifentrine) is a long actingpotent and specific dual inhibitor of PDE 3/4 (phosphodiesterase 3 and 4). RPL554 displays a broad range of both bronchoprotective and anti-inflammatory activities. AlsoRPL554 synergizes with anti-muscarinic drugs in inhibition of ASM tone. RPL554 (Ensifentrine) exhibits anti-inflammatory effects through reduced production of the monocyte chemoattractant protein-1 (MCP-1) and granulocyte monocyte colony stimulating factor (GM-CSF) in cystic fibrosis bronchial epithelial cells during challenge with Interleukin-1β. |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|